



**meetings
in a box**

ROAD TO 
ESGO 2026

A cura di Eugenia Cella, Savona

ROAD TO... ESGO 2026

Copenhagen 26-28 Feb 2026



OVARIAN CANCER

ENDOMETRIAL CARCINOMA

CERVICAL CANCER

OVARIAN CANCER

PLATINUM-RESISTANT RECURRENT OVARIAN CANCER

KEYNOTE-B96 (N. Colombo – Abstract 526) Phase 3 trial

Pembrolizumab vs placebo plus weekly paclitaxel ± bevacizumab

ROSELLA (D. Lorusso – Abstract 906) Phase 3 trial

Nab-paclitaxel ± "Relacorilant"

(G. Levin – Abstract 274) Phase 2 trial

P62/SQSTM1-encoding plasmid (elenagen) + gemcitabine

OVARIAN CANCER

FIRST LINE OVARIAN CANCER

ICON8B (A. Clamp – Abstract 405) Phase 3 trial

First-line weekly dose-dense chemotherapy + bevacizumab VS three-weekly chemotherapy + bevacizumab in high-risk stage III-IV epithelial ovarian cancer

OVARIAN CANCER

FIRST LINE OVARIAN CANCER

ICON8B (A. Clamp – Abstract 405) Phase 3 trial

First-line weekly dose-dense chemotherapy + bevacizumab VS three-weekly chemotherapy + bevacizumab in high-risk stage III-IV epithelial ovarian cancer

SURGERY

SUROVA (N. Manzour – Abstract 838)

HIPEC after interval debulking surgery (Ro)

ENDOMETRIAL CARCINOMA

MOLECULAR CLASSIFICATION

F.C. Wakkerman – Abstract 730

No prognostic role for FIGO grading in mismatch repair deficient endometrial carcinomas

T. Occhiali – Abstract 688

Old and new risk classification system: which predicts recurrence better?

CERVICAL CANCER

AK 104 (X. Wu – Abstract 679) Phase 2 trial

Cadonilimab monotherapy in recurrent cervical cancer

SURGERY

F. Wakkerman – Abstract 730

Robotic minimally invasive surgery

R. Koclan – Abstract 209

Lower-limb lymphoedema after sentinel lymph node biopsy VS pelvic lymphadenectomy